Recombinant Human Anti-CD8 x Human Anti-PSCA Bispecific Antibody (IgG-Fv) (BSGV-H304)

Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD8 antibody variable domain is fused to the C terminal of an IgG of anti-PSCA antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD8 & PSCA

Type

IgG-Fv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Prostate cancer

Targets

Target 1

CD8

Gene ID

925

UniProt ID

P01732

Alternative Names

CD8A; CD8a molecule; Cluster of differentiation 8; CD8; MAL; p32; Leu2

Target 2

PSCA

Gene ID

8000

UniProt ID

D3DWI6

Alternative Names

PSCA; prostate stem cell antigen; PRO232

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD8 x Human Anti-PSCA Bispecific Antibody (IgG-Fv) (BSGV-H304). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD8 x Human Anti-PSCA Bispecific Antibody (IgG-Fv) (CAT#: BSGV-H304)

Specifications

Targets

Customer Reviews and Q&As